Advanced in Hemolytic Anemia

Andre Efira

CHU Brugmann
Brussels, BRU, BE 
Advanced in Hemolytic Anemia
CHU Brugmann
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Andre Efira practices in Brussels, Belgium. Mr. Efira is rated as an Advanced expert by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Hemolytic Anemia, Hemoglobinopathy, and Congenital Hemolytic Anemia.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Hemolytic Anemia.

Gender
Male

Locations

CHU Brugmann
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: FOLFOX
Study Phase: Not Applicable
View 1 Less Clinical Trial

15 Total Publications

Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes.
Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes.
Journal: EJHaem
Published: July 06, 2020

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Efira's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile